Pharmaceuticals

AstraZeneca

Salesforce

Conference Minutes

INFA

VEEV

TWTR

08391

4502

Below is Dolphin Research's Trans of $Salesforce(CRM.US) FY26 Q4 earnings call.For our earnings analysis, cf. 'Salesforce: The AI replacement thesis sweeps the field — has the SaaS leader been cast aside?'Key takeaways recap1) Q1 guidance: revenue of $11.03–11.08bn, implying reported growth of ~12–13%.Management also guides Q1 CRPO to grow ~14% YoY on a reported basis ...

ServiceNow

Informatica

Veeva Systems -CL

Sunrun

AstraZeneca PLC

Pfizer

Twitter

CORNERSTONE TEC

Takeda Pharmaceutical Co. Ltd.

CRM Trans: Organic rev. growth to re-accelerate in H2 FY

---

AstraZeneca's EMERALD-3 Trial: STRIDE Plus TACE Plus Lenvatinib Improves PFS in HCC Patients

AstraZeneca Announces Phase III Trial Results for Efzimfotase Alfa

Enhertu Approved in China for HER2-Positive Breast Cancer Neoadjuvant Therapy

AstraZeneca Receives Approval for Selumetinib Capsules in China

Multinational Pharma Executives Intensify Activities in China, Demonstrate Strong Confidence in the Market

AstraZeneca's Tezspire Approved for Two Indications in China

AstraZeneca and Daiichi Sankyo's Enhertu Approved by China's NMPA for New Breast Cancer Treatment

AstraZeneca's Tezolizumab Significantly Reduces Risk of Acute Exacerbations in COPD

Jiangsu Party Secretary Xing Changxing Meets with AstraZeneca CEO to Deepen Cooperation

Deutsche Bank analyst maintains sell rating on AstraZeneca

AstraZeneca Receives 'Moderate Buy' Consensus Rating from Analysts

AstraZeneca signs agreement with Guangzhou to build RDC production base

Wall Street Zen Upgrades AstraZeneca Stock Rating to Buy

AstraZeneca Plans to Build a Radiopharmaceutical Production Supply Base in Guangzhou

AstraZeneca Plans to Establish a Commercial Cell Therapy Production and Supply Base in Shanghai

AstraZeneca to Build a Cell Therapy Commercial Manufacturing Site and Innovation Center in Shanghai

AstraZeneca Pauses Chronic Obstructive Pulmonary Disease Burden Study in Egypt

AstraZeneca India Obtains Import Permit for Durvalumab for New Indication

Berenberg Analyst Maintains Buy Rating on AstraZeneca

AstraZeneca's Imfinzi Approved by the EU for Early Stage Gastric Cancer Perioperative Therapy

Visionary

Sky Quarry

TMD Energy

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Semilux

Cocrystal Pharma

Sidus Space

Swarmer

Franklin Covey

Biodexa Pharmaceuticals

Earning Release Date

财报预告

FY2026 Q1 Earning Release 2026.04.28 (EST)

AstraZeneca PLC (AZN.US) Q4 2025 Earnings Conference Call

AstraZeneca PLC (AZN.US) Q3 2025 Earnings Conference Call

AstraZeneca PLC (AZN.US) Q2 2025 Earnings Conference Call

AstraZeneca PLC (AZN.US) Q4 2024 Earnings Conference Call

AstraZeneca PLC (AZN.US) Q3 2024 Earnings Conference Call

Eli Lilly

ROCHE HOLDINGS AG

Roche

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Otsuka Pharmaceutical

Daiichi Sankyo

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

AstraZeneca(AZN.US)

AstraZeneca Stock Performance Chart

Trending